Wednesday, 22 April 2020

Chordoma Disease Market Size Estimation By Top Manufacturer, Latest Trends And Global Industry Forecast 2019 To 2023

Market Scenario
Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market trends.
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Regionally, the Americas chordoma disease market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global chordoma disease market owing to the increasing demand for targeted therapies and growing health concerns. As per an estimate by the American Cancer Society, about 3,300 new cases of bone cancer were diagnosed in 2016 with a death toll of about1490. Thus, the high prevalence of chondroid chordomas is the major hurdle in the market growth.
Key Players
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Regional Analysis                    
The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).
The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Posted by at No comments:

Venous Blood Collection Devices Market Shares Analysis, Key Development Strategies And Forecasts Till 2023

Market Scenario
The Global Venous Blood Collection Devices Market is expected to expand at a CAGR of 9.3% over the forecast period of 2019-2023, reveals Market Research Future (MRFR) in a detailed study.
Venous blood collection devices are vessels used for collection, sampling, and testing blood samples. These devices are easy to handle, provide mechanical protection as well as protection from contamination and radiation. Moreover, these blood collection devices offer the exact filling volume.
The global venous blood collection devices market trends are driven by the increasing diagnostics and screening for numerous diseases, increasing health awareness leading to growing demand for blood collection devices for sampling, and with the growing preference for disposable products. Product development can be an attractive strategy for expanding the global venous blood collection devices market.
However, restraints that are likely to hinder the growth of the venous blood collection devices market include risks associated with contamination, pressure on prices, and low-quality products from unknown manufacturers. 
The global burden of chronic diseases is increasing at an alarming rate which induces high demand for screening services and consequently boosts the growth of the global venous blood collection devices market. This further complemented by growing disposable income and high health awareness among consumers. To meet the massive demands, medical device manufacturers are endeavoring towards product improvement which jhas resulted in teh devleopment of advanced venous blood collection devices that can be used for safer blood collection. Furthermore expansdion in product oportfolio by key medical device manufacturers have resulted in teh consolidation of teh global venous blood collection devices market. On the other hand, the growth of the market might be undermined by risks related to contamination, pricing pressure, and substandard product from local manufacturers.
Key Players
Some of the key players in the global venous blood collection devices market are Becton, Dickinson and Company (U.S), Bio-Rad Laboratories, Inc. (U.S), NIPRO Medical Corporation (Japan), Qiagen NV (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Greiner Bio One International GmbH (Greiner Group) (Austria), Terumo Medical Corporation (Japan), Sekisui Chemical Co., Ltd. (Japan), Sarstedt AG & Co (U.S.), F.L. Medical (Italy), Narang Medical (India), Soya Green Tec Co., Ltd. (South Korea), Biosigma (U.S.), Vital Diagnostice (ELITech Group) (U.S.), Improve Medical Technology Co. Ltd. (U.S.), Hongyu Medical (China), SanLI (Myanmar.), KHB (U.S.), Zhejiang Gongdong Medical Technology Co., Ltd. (China), CDRICH (China), Radiometer Medical ApS (Danaher Corporation/ Danrad ApS) (Denmark), Medtronic Plc (U.S.), Fisher Scientific (Thermo Fisher Scientific Inc.) (U.S.), Kabe Labortechnik GmbH (Germany), Allegro Medical Supplies Inc. (Scrip Products Corporation) (U.S.), and others.
Segmentation
The global venous blood collection devices market has been segmented on the basis of type, material, application, and end-user.
On the basis of material, the global venous blood collection devices market is segmented into plastic, glass, stainless steel, ceramic, and others.
On the basis of type, the market is segmented into blood collection tubes, needles, vacuum blood collection system, microfluidic system, micro-container tubes, micro-hematocrit tubes, warming devices, and others. Other devices include venous cannula and blood bags. The blood collection tube is further sub-segmented into plasma separation tube, heparin tube, serum separating tube, EDTA tube, and others.
On the basis of application, the venous blood collection market is segmented into vein blood gas sampling and intraoperative blood salvage. Vein blood gas sampling is further sub-segmented into the diagnosis of disease and acid-base status monitoring.
On the basis of end-user, the global venous blood collection devices market is segmented into hospitals and clinics, the point of care, blood donation centers, diagnostic centers, and others.
Regional Analysis                     
The global venous blood collection devices market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure. Gulf nations such as the U.A.E. and Saudi Arabia are projected to drive the Middle Eastern and African market. The government has undertaken various awareness programs for safe blood transfusion procedures which are further improving the health conditions in underdeveloped regions of Africa.
The Americas region accounted for the largest market share of the global venous blood collection devices market owing to the fastest uptake of new surgical techniques and instruments in the North American region, thus driving the venous blood collection devices market. Moreover, the extensive use of screening techniques and high expenditure on health care in the U.S. is driving the market growth. The greater awareness in developed regions along with the good reimbursement scenario drive the Americas venous blood collection devices market.
The European region accounted for the second largest market owing to high income and healthcare penetration. The Asia Pacific region is expected to increase during the forecast period owing to the growing healthcare sector in leading regions such as China and India. The major driving factors of the venous blood collection devices market are the increasing geriatric population, growth in demand for safe blood assortment technologies, increase in demand for improved blood sampling techniques, and increase in preference towards disposable products for the laboratory.
Posted by at No comments:

Epilepsy Diagnosis & Treatment Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

Synopsis of the Global Epilepsy Diagnosis & Treatment Market
Increasing prevalence of epilepsy, rising number of traumatic brain injury cases, growing geriatric population, and rising healthcare expenditures are the major drivers for the global epilepsy diagnosis and treatment market trends. However, high cost of therapeutic surgeries, low per capita healthcare expenditure, and lack of awareness for the disease in emerging economies are estimated to restrain the market growth during the projected period. The global epilepsy diagnosis and treatment market is estimated to grow at an approximate CAGR of 6.3% during the forecast period.
Segmentation
The global epilepsy diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, and end-user. On the basis of type, the market is segmented into idiopathic, cryptogenic, symptomatic, and others. On the basis of diagnosis, the market is segmented into neurological exam, blood test, imaging, and others. The imaging segment is sub-segmented into electroencephalogram, computerized tomography, magnetic resonance imaging, positron emission tomography, and others. On the basis of treatment, the market is segmented into medication, surgery, brain stimulation, and others. The medication segment is sub-segmented into acetazolamide, carbamazepine, clobazam, and others. The surgery segment is sub-segmented into hemispherectomy, corpus callosotomy, resection surgery, and others. The brain stimulation segment is sub-segmented into deep brain stimulation, responsive neurostimulation, and others. On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Regional Analysis
The Americas dominate the global epilepsy diagnosis and treatment market, which can be attributed to the presence of a well-developed healthcare sector and huge patient population within the region. Moreover, increasing number of head trauma cases boosts the American market. Europe holds the second largest market share owing to the availability of funds for research, presence of a well-developed healthcare sector, and government support. Followed by Europe, the Asia Pacific region is projected to be the fastest growing region for the global epilepsy diagnosis and treatment market. Presence of developing healthcare sector, along with emerging economies of the Asia Pacific region boosts the market growth. The Middle East & Africa has the least share in the global epilepsy diagnosis and treatment market, owing to the low per capita healthcare expenditures, lack of awareness for the disease, and stringent government policies, especially in the African region. On the other hand, the Middle East region within the Middle East & Africa is estimated to be fastest growing region due to growing healthcare expenditures and presence of the developed economies, such as Kuwait, Qatar, Dubai, and others.
Key Players
The key players for the global epilepsy diagnosis and treatment market are Pfizer, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), UCB Pharma Ltd. (U.K), Abbott (U.S.), GlaxoSmithKline plc (U.K), Novartis International AG (Switzerland), Sanofi S.A. (France), Shire (Republic of Ireland), Medtronic (U.S.), NeuroWave Systems Inc. (U.S.), Natus Medical Incorporated. (U.S.), Siemens Ltd. (Germany), and others.
Posted by at No comments:

Worldwide Ebstein’s Anomaly Market Top 10 Players Universal Analysis, Industry Demand And 2023 Forecast

Market Scenario:
Ebstein's anomaly is a rare congenital disease that occurs due to improper development of the tricuspid valve in the first eight weeks of fetal growth. This disorder occurs when the tricuspid valve that divides the two chambers of the right side of the heart does not form correctly.
The global Ebstein’s Anomaly market is driven by the increasing number of congenital heart diseases and growing population; growing market players has increased the scope of Ebstein’s Anomaly market. Technological advancements, owing to which new and advanced products are being launched in the market, is another factor propelling the growth of this market.
Ebstein's anomaly may be due to many factors, including genetics and the environment. Children born in a family with a history of heart defects may be more likely to have Ebstein's anomaly. The mother's exposure to certain medications, such as lithium, can lead to Ebstein's anomaly in the child.
However, varied stringency of regulatory procedures across the globe and the presence of complex regulatory procedures may hinder the growth of this market.
The global Ebstein’s Anomaly market share is expected to grow at a CAGR of 9.0% during the forecast period.
Key Players                                                                                                         
Some of the key players in fungal eye infection market are Ebstein’s Anomaly market are Abbott Vascular, Boston Scientific Corporation, Cordis Corporation, Edwards Lifesciences, Ge Healthcare, Gore Medical, Medtronic, Inc., Numed, Inc., Siemens Healthcare, St. Jude Medical, and Toshiba Corporation among others.

Segmentation                                                                                                                                            
The global Ebstein’s Anomaly market is segmented on the basis of treatment, diagnosis and end users.
On the basis of diagnosis Ebstein’s Anomaly market is segmented into echocardiogram, electrocardiogram (ECG) chest x-ray, cardiac MRI, Holter monitor, pulse oximetry, exercise stress test, electrophysiology study, and cardiac catheterization.
On the basis of the treatment, the market is segmented medications and surgical treatment. Surgical Treatment is further segmented into tricuspid valve repair, tricuspid valve replacement, closure of the atrial septal defect, and maze procedure.
On the basis of end users, the market is segmented into hospitals & surgical centers, and specialty clinics.
Regional Analysis
North America Ebstein’s Anomaly market is rapidly growing in the American region. On a regional basis, the Americas is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of congenital disorders and growing  population has increased the scope for the Ebstein’s Anomaly market in North America. According to CDC (Centre for Disease Control), it was estimated that about 1 million U.S. children and about 1.4 million U.S. adults were living with CHDs.  Additionally, CHDs affect nearly 1% of―or about 40,000―births per year in the United States.
Europe is the second largest market and holds a healthy share in the global Ebstein’s Anomaly market. The European market is expected to grow steadily during the forecast period owing to the skilled professionals and availability of advanced and accessible treatment facilities. Additionally, wide research and development activities for the treatment of rare disease and increasing government funding boost the market growth.  
Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes is the major driver for the market growth. India is the fastest growing region owing to the increasing population. Rising awareness about the health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drives the market.
The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.
Posted by at No comments:

Worldwide Transthyretin Amyloidosis (ATTR) Market Segmentation And Analysis By Recent Trends And Growth Prospects By Regions To 2023

Transthyretin (TTR) Amyloidosis Market Analysis: Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), Gender (Male & Female), Treatment (Small Molecule Treatment), & End-User (Ambulatory Surgical Center, Clinics) – Global Forecast Till 2023                                                                                                                          
Market Scenario
The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period.  Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.
Top Market Players
  • Alnylam Pharmaceuticals
  • Pfizer
  • Merck
  • Ionis Pharmaceuticals Inc.
  • Corino Therapeutics Inc
  • Arcturus Therapeutics
  • Proclara Bioscience
Market Segmentation                                                                                                                          
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy,  organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.
Regional Market Summary
Transthyretin Amyloidosis (ATTR) Market share and trends analysis on Regional basis, Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.
Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period.  Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.
Europe is the second largest market and holds a healthy global Transthyretin (TTR) amyloidosis market share. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform.  It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.
Posted by at No comments:

Coronary Stent Market Opportunities, Drivers, Manufacturers, Analysis And Forecasts Till 2023

Coronary Stent Market Report: By Type (Bare-Metal Stents, Drug-Eluting Stents, and Bio Absorbable Stents), by Mode of Delivery (Balloon-Expandable Stents and Self-Expanding Stents), by End-User (Hospitals & Clinics) - Global Forecast Till 2023
Coronary stents are small stretchy tube-like devices used to expand the arteries of the patient in order to prevent blockage. A coronary stent is inserted into the artery of a patient suffering from a coronary disease due to the build-up of plaque. It is used for widening the narrowed arteries, and it helps in reducing chest pain and the chance of heart attack
The global coronary stent market is mainly driven by the high prevalence of heart-related diseases and huge demand for diagnosis and treatment methods. Additionally, the increasing availability of diagnostic services for coronary heart diseases also fuels the growth of the market. Moreover, favorable reimbursement policies are likely to boost the market growth.
Many private and government insurance organizations are present in developed countries. Over 50 private insurance companies are present in the U.S. The policies cover more than 75% of the cost of the devices and treatment. For instance, under the Medicare plan in the U.S., if the average cost of three stents is approximately USD 10,000, then USD 7,500 is reimbursed. Additionally, in developed countries such as the U.K., Canada, and Germany, other similar reimbursement policies are available. On the other hand, alternative treatment methods for coronary arteries disease and numerous cases of product recalls may hamper the market growth.
The global coronary stent market is expected to have a CAGR of 7.8% during the forecast period.
Intended Audience
  • Medical Device Manufacturers
  • Medical Device Suppliers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors
Segments  
The global coronary stent market is segmented on the basis of type, mode of delivery, material, and end-user.
On the basis of type, the market is segmented into bare-metal stents, drug-eluting stents, and bio absorbable stents.
On the basis of mode of delivery, the market is segmented into balloon-expandable stents and self-expanding stents.
On the basis of material, the market is segmented into metallic stents, cobalt chromium, platinum chromium, nickel titanium, stainless steel, and others.
On the basis of end-user, the market is segmented into hospitals and clinics, cardiac centers, ambulatory surgical centers, and others.
Regional Analysis of the Global Coronary Stent Market                       
The American coronary stent market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven by the increasing patient population suffering from coronary heart disease, growing investment in healthcare, and increasing geriatric population. Furthermore, the U.S. is the largest market in North America owing to the presence of a large number of market players manufacturing coronary stents and the increasing awareness about risk factors for the coronary heart disease. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for medical devices with progress in coronary stent devices. South America is expected to be the fastest growing market due to technologically advanced devices for diagnosis and the increasing demand for treatment options of the coronary heart disease.
The European coronary stent market exhibits a positive growth with an increasing emphasis on the diagnosis of heart diseases and other related diseases. Moreover, Germany and the U.K. are the major contributors to the growth of the market. Additionally, the increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market.  
Asia Pacific is expected to be the fastest growing market whose growth is attributed to the increasing burden of cardiovascular diseases and increasing focus on early diagnosis and treatment of heart diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among adults, and addiction to smoking. Additionally, the increasing environmental pollution and exposure to harmful chemicals also attribute to the growth of the market.
The Middle Eastern and African market for coronary stents exhibits a steady rise with an increase in the number of healthcare facilities providing treatments for chronic conditions and the flourishing growth of the medical device sector especially diagnostic devices. In the African region, the awareness about the coronary heart disease is increasing the growth of the market.
Key Players in the Global Coronary Stent Market        
Some of the key players in this market are BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), Medtronic plc (Ireland), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), and Translumina GmbH (Germany), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.),STENTYS SA (France), Biosensors International Group, Ltd. (Singapore), Kyoto Medical Planning Co. Ltd. (Japan), Elixir Medical Corporation (U.S.), and Reva Medical Inc. (U.S.), and others.
Posted by at No comments:
Labels:

Global Neuroendoscopy Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2023

Market Scenario:
Neuroendoscopy is characterized as a minimally-invasive surgical procedure which is extensively utilized to remove tumors. The excision occurs via small holes present in the skull, i.e., through the mouth or nose. In neuroendoscopy procedures, a small telescopic device equipped with a high-resolution video camera and an eyepiece is used. This gives the neurosurgeons, an ability to navigate and effectively access the parts of the brain that could not be addressed by traditional surgery. Some of the other advantages of neuroendoscopy include fast recovery, minimal scarring, and others.
The increasing prevalence of brain tumors is a major driver for the market growth. According to a study published by the Neuro-Oncology Journal in 2015, the global incidence rate for all types of brain tumors was estimated to be about 10.82 per 100 000 persons.
The increasing prevalence of brain tumors, increasing demand for minimally invasive surgical procedures, growing geriatric population, and favorable reimbursement policies are estimated to drive the global neuroendoscopy devices market growth, during the forecast period. However, a dearth of physicians and the high cost of neuroendoscopy procedures and equipment are projected to restrain the market growth during the forecast period.
Global Neuroendoscopy Market is expected to grow at an approximate CAGR of 5.2% during the forecast period.
According to the National Institute of Health in 2016, the global geriatric population is estimated to be more than triple from 2015 to 2050, i.e., it is projected to grow from 126.5 in 2015 million and reach 446.6 million by 2050. However, a shortage of physicians and high cost for neuroendoscopy procedures and equipment are projected to restrain the market growth during the forecast period. The Association of American Medical Colleges in 2016 stated that the demand for physicians continued to grow at a higher rate, exceeding the supply. The projected total physician shortfall by 2025 is estimated to be in between 61,700 and 94,700.
Key players
The key players in the global neuroendoscopy market are KARL STORZ (Germany), B. Braun (Germany), Ackermann Instrumente (Germany), Adeor Medical (Germany), Hangzhou Hawk Optical Electronic Instruments (China), Machida Endoscope (Japan), Tonglu Wanhe Medical Instrument (China), Schindler Endoskopie (Germany), Clarus Medical (U.S.), LocaMed (U.K), Visionsense Corporation (U.S.), Olympus Corporation (Japan), Zeiss International (Germany), Stryker (U.S.), Medtronic (U.S.), and others.
Segmentation
The global Neuroendoscopy market is segmented on the basis of product, application, usability, and end-user.
On the basis of products, the market is segmented into rigid neuroendoscopes and flexible neuroendoscopes. The rigid neuroendoscopes segment is sub-segmented into rigid video scopes and rigid fiberscopes. On the basis of application, the market is categorized into transnasal neuroendoscopy, intraventricular neuroendoscopy, and transcranial neuro-endoscopy. On the basis of usability, the market is segmented into reusable neuroendoscopes and disposable neuroendoscopes. On the basis of end-users, the market is segmented into hospitals, clinics, medical research centers, and others.
Regional Analysis
The Americas dominates the global neuroendoscopy market. Factors such as the increasing prevalence of brain tumors, the presence of a well-developed healthcare sector, and huge health care expenditures within the region drive the market growth within the region. Moreover, the presence of key players such as Stryker and Medtronic, besides others and the growing geriatric population within the region fuel the market growth.
Europe stands second in the global neuroendoscopy market due to the increasing demand for minimally invasive surgeries, rising availability of funds for research and development, and a huge patient population. According to the Cancer Research U.K., the total number of new cases for brain tumor was estimated to be about 11,432 in 2015.  
Followed by Europe, Asia Pacific stands third in the global neuroendoscopy market. Moreover, the region is projected to be the fastest growing region in the global market. This can be attributed to the presence of developing economies such as China, growing patient population, developing healthcare sector, and increasing per capita healthcare expenditures. Additionally, favorable government policies support the market growth. Medical tourism and rising geriatric population are estimated to fuel the market growth. According to the Indian Brand Equity Foundation, the medical tourism industry in India is estimated to grow rapidly and reach USD 9 billion by 2020.
The Middle East and Africa holds the least share in the global neuroendoscopy market due to the presence of poor economies, stringent government policies, lack of awareness, low per capita income, and poor availability of healthcare services, especially within the African region. A majority of the neuroendoscopy market within the region is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure.
Posted by at No comments:
Subscribe to: Comments (Atom)